Prometheus 360™ Precision Medicines Platform Delivers Individualized Treatments to GI Patients

Gastrointestinal (GI) diseases, are complex and debilitating disorders that affect millions of people worldwide.  Currently available therapies attempt to treat symptoms with “one-size fits all” solutions that don’t work effectively for many patients. 

Prometheus Biosciences’ mission is to create a new paradigm in patient care. Our powerful precision medicines platform leverages proprietary technology to translate complex and deep patient data into precision therapeutics and diagnostics, providing an effective treatment solution for every GI patient.

World’s Largest
GI Biobank

For the past 15 years, we have built a highly curated database and biorepository containing more than 200,000 samples linked to extensive longitudinal clinical data from over 20,000 patients.


Samples are subjected to ‘big data’-style profiling including genetics, serologics, transcriptomics and microbiomics, to uncover unprecedented insights about immunological networks that drive GI disease.

Drug Target &
Biomarker Discovery

Utilizing state-of-the-art data mining and machine-learning analysis approaches, we restratify complex GI diseases into biologically homogeneous subgroups to discover novel druggable targets with unique biomarkers.

Precision Therapeutic Products

We develop targeted therapeutic options that offer superior efficacy to patients and an accelerated path to the market.

Companion Diagnostics

In parallel, we design companion diagnostic tests to predict response to these new therapies, ensuring the right drug for the right patient.